Compare ALEMBIC with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs ABBOTT INDIA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC ABBOTT INDIA ALEMBIC/
ABBOTT INDIA
 
P/E (TTM) x 55.6 47.1 118.1% View Chart
P/BV x 4.8 15.4 31.2% View Chart
Dividend Yield % 0.2 0.4 47.6%  

Financials

 ALEMBIC   ABBOTT INDIA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
ABBOTT INDIA
Mar-19
ALEMBIC/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs728,834 0.8%   
Low Rs345,458 0.6%   
Sales per share (Unadj.) Rs4.71,731.1 0.3%  
Earnings per share (Unadj.) Rs6.1211.9 2.9%  
Cash flow per share (Unadj.) Rs6.2219.9 2.8%  
Dividends per share (Unadj.) Rs0.2065.00 0.3%  
Dividend yield (eoy) %0.40.9 41.5%  
Book value per share (Unadj.) Rs40.7945.2 4.3%  
Shares outstanding (eoy) m267.0321.25 1,256.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.34.1 272.9%   
Avg P/E ratio x8.733.7 25.7%  
P/CF ratio (eoy) x8.532.5 26.1%  
Price / Book Value ratio x1.37.6 17.2%  
Dividend payout %3.330.7 10.7%   
Avg Mkt Cap Rs m14,139151,848 9.3%   
No. of employees `000NA3.5 0.0%   
Total wages/salary Rs m2074,356 4.8%   
Avg. sales/employee Rs ThNM10,555.5-  
Avg. wages/employee Rs ThNM1,249.9-  
Avg. net profit/employee Rs ThNM1,292.2-  
INCOME DATA
Net Sales Rs m1,25536,786 3.4%  
Other income Rs m3701,133 32.7%   
Total revenues Rs m1,62537,919 4.3%   
Gross profit Rs m1116,047 1.8%  
Depreciation Rs m38169 22.3%   
Interest Rs m223 7.6%   
Profit before tax Rs m4426,989 6.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m242,485 1.0%   
Profit after tax Rs m1,6304,503 36.2%  
Gross profit margin %8.916.4 53.8%  
Effective tax rate %5.435.6 15.2%   
Net profit margin %129.812.2 1,060.7%  
BALANCE SHEET DATA
Current assets Rs m1,86727,610 6.8%   
Current liabilities Rs m5918,569 6.9%   
Net working cap to sales %101.651.8 196.4%  
Current ratio x3.23.2 98.0%  
Inventory Days Days9460 156.5%  
Debtors Days Days7427 268.4%  
Net fixed assets Rs m1,7911,057 169.4%   
Share capital Rs m534213 251.3%   
"Free" reserves Rs m10,32419,873 51.9%   
Net worth Rs m10,85820,086 54.1%   
Long term debt Rs m410-   
Total assets Rs m11,59129,409 39.4%  
Interest coverage x260.9311.6 83.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.11.3 8.7%   
Return on assets %14.115.4 91.5%  
Return on equity %15.022.4 67.0%  
Return on capital %15.234.9 43.5%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m19369 5.3%   
Fx outflow Rs m2644,918 5.4%   
Net fx Rs m-244-4,549 5.4%   
CASH FLOW
From Operations Rs m2364,991 4.7%  
From Investments Rs m-224-2,570 8.7%  
From Financial Activity Rs m-27-1,428 1.9%  
Net Cashflow Rs m-15993 -1.5%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 7.9 2.5%  
FIIs % 9.7 0.1 9,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 17.1 152.6%  
Shareholders   54,701 18,270 299.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   SANOFI INDIA  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare ALEMBIC With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 500 Points Lower; Dow Futures Down by 77 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 553 points, down 1.1% at 47,794 levels.

Related Views on News

PROCTER & GAMBLE HEALTH at All Time High; BSE HEALTHCARE Index Down 0.9% (Market Updates)

Jan 27, 2021 | Updated on Jan 27, 2021

PROCTER & GAMBLE HEALTH share price has hit an all time high at Rs 7,473 (up 3.7%). The BSE HEALTHCARE Index is down by 0.9%. Among the top gainers in the BSE HEALTHCARE Index today are PROCTER & GAMBLE HEALTH (up 3.7%) and ABBOTT INDIA (up 0.5%). The top losers include ERIS LIFESCIENCES and BIOCON (down 0.1%).

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Jan 27, 2021 03:36 PM

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - ALKEM LABORATORIES COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS